On Pipeline Priorities
Dr. Agarwal: We have built a focused pipeline targeting validated oncology pathways with differentiated approaches. Our programs address significant unmet needs in both solid tumors and hematological malignancies.
Our lead program is advancing toward key clinical milestones, and we have a robust pipeline of follow-on candidates that leverage our core technology platforms.
On Development Approach
Q: How do you approach clinical development?
Dr. Agarwal: Efficiency is critical in oncology development. We use biomarker-driven patient selection to enrich for responders and optimize probability of success. This approach allows us to generate meaningful data with smaller, faster trials.
We also invest heavily in translational science to understand mechanisms of response and resistance. This informs both patient selection and potential combination strategies.
On 2026 Outlook
Q: What should investors expect in 2026?
Dr. Agarwal: 2026 will be transformational for Kairos. We expect multiple data readouts that could significantly advance our pipeline. Key milestones include our Phase 2 data in our lead indication and initiation of additional clinical programs.
On Competitive Position
Q: How is Kairos differentiated?
Dr. Agarwal: Our differentiation comes from our deep understanding of tumor biology and our ability to translate that into effective therapies. We are not pursuing me-too approaches but rather novel mechanisms that address resistance and improve outcomes.